Safety, efficacy, tolerability and pharmacokinetics of NNC 0070-0002-0182 in overweight or obese healthy male volunteers.

Trial Profile

Safety, efficacy, tolerability and pharmacokinetics of NNC 0070-0002-0182 in overweight or obese healthy male volunteers.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2016

At a glance

  • Drugs NNC 0070-0002-0182 (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Oct 2009 Actual patient number amended from 60 to 101 as reported by ClinicalTrials.gov.
    • 16 Oct 2008 Actual patient number (60) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top